A Phase 2 interventional study of Xarelto (Rivaroxaban, BAY59-7939) and Xarelto (Rivaroxaban, BAY59-7939) in Venous Thrombosis and Deep Vein Thrombosis, sponsored by Bayer. Completed at 110 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-07.
Sponsored by Bayer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing rivaroxaban in Venous Thrombosis — 5 open to participants now, 6 under way, 2 of them phase 3. Rivaroxaban · Venous Thrombosis.
Among the 36 studies testing rivaroxaban in Venous Thrombosis, this one is the 11th largest by enrollment, is the only one that started in 2004, is one of 4 in phase 2, and was the 4th registered.
785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.
Browse Venous Thrombosis studies →5 of the 36 studies testing rivaroxaban in Venous Thrombosis are open now, in 6 countries. Recruiting first, the newest first:
Mayo Hospital Lahore · Sites in Pakistan
Ages 18–80
Prof. Stavros Konstantinides, MD · Sites in Austria, Germany
Ages 18–85
University Hospital, Angers · Sites in France
Ages 18+
Science Valley Research Institute · Sites in Brazil
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 18+
By country, each count listing its studies:
Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 13 · Phase 4 10
First in 2004; this study’s year is marked. 1 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 613 is above the median of 152 across 477 interventional studies indexed under Venous Thrombosis.
Median enrollment 120 across the 36 interventional studies. Of the 24 that completed or were terminated, 8 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 36 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
23 studies in Venous Thrombosis by Bayer: none open now, none under way, none of them phase 3. Of 23 finished, 6 (26%) have results posted.
Among the 23 studies in Venous Thrombosis by Bayer, this one is the 5th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2004, is one of 5 in phase 2, and was the 4th registered.
Bayer’s Venous Thrombosis studies by the year they started, since 2004.
3 of the studies testing rivaroxaban in Venous Thrombosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06611319Phase 3Prof. Stavros Konstantinides, MDENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty | 2027-03 |
| NCT04694248First Affiliated Hospital of Zhejiang UniversityAnticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting | 2026-12-31 |
| NCT03129555Herlev and Gentofte HospitalThe Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE) | 2027-03-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies testing rivaroxaban in Venous Thrombosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 23 in Venous Thrombosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the safety and efficacy of BAY59-7939 with the safety and efficacy of the licensed drug enoxaparin and a licensed oral vitamin K-antagonist and to find the optimal dose of BAY59-7939 for the anticipated phase III trials and for the future clinical use.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Xarelto (Rivaroxaban, BAY59-7939)
Drug: Xarelto (Rivaroxaban, BAY59-7939)
Drug: Xarelto (Rivaroxaban, BAY59-7939)
Drug: Xarelto (Rivaroxaban, BAY59-7939)
Drug: Enoxaparin/Vitamin K-Antagonist
10 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
20 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
30 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
40 mg od main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
Drug pages: Enoxaparin · Vitamin K Antagonist
Enoxaparin/Vitamin K-Antagonist main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84). Enoxaparin was to be administered 1mg/kg bid sc for about 5-7 days. It was to be discontinued when INR was within the therapeutic range 2-3 for 2 consecutive days
Response to treatment as determined by a Complete Compression Ultra sound (CCUS)
Time frame: 21 days
Response to treatment as determined by a Complete Compression Ultrasound (CCUS) and perfusion lung scan
Time frame: Day 21
Response to treatment and residual vein diameter as assessed by Complete Compression Ultrasound (CCUS)
Time frame: Day 84
Incidence of symptomatic and confirmed recurrence or extension of Deep Vein Thrombosis (DVT)
Time frame: Day 1-84
Composite endpoint of symptomatic and confirmed recurrence and extension of Deep Vein Thrombosis (DVT) and symptomatic Pulmonary Embolism (PE) (nonfatal DVT and/or nonfatal PE) and deaths during the 3 months treatment period
Time frame: Day 1-84
Incidence of symptomatic and confirmed recurrence and extension of Deep Vein Thrombosis (DVT) and symptomatic Pulmonary Embolism (PE) within 30 days after stop of treatment with study drug
Time frame: Day 1-114
Showing the first 100 of 110 sites across 19 countries. Choose a country and city above to see the rest.
The record gives a start of Mar 2004, a primary completion of Oct 2005 and a completion of Oct 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rivaroxaban